Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 242-362-4 | CAS number: 18479-58-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Information from in vivo and in vitro metabolism studies with the structurally-related tertiary monoterpene alcohol, linalool, was used for dihydromyrcenol.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
Additional information
No information was identified relating to the absorption, disposition or metabolism of dihydromyrcenol. Information was available for the structurally similar analogue chemical, linalool. Linalool was rapidly absorbed following oral administration in rats and excreted primarily in the urine with lesser amounts in the expired air and feces. Thus, following a single dose of 500 mg/kg bwt of 1,2-[14C]linalool as a 25% solution in propylene glycol, 57% was excreted in the urine, 23% in expired air and 15% in feces after 72 hours (Parke et al., 1974). Approximately 50% of the total administered dose was eliminated within 18 hours. Only 3% of the administered radioactivity was detected in tissues after 72 hours with 0.5% in the liver, 0.6% in the gut, 0.8% in the skin and 1.2% in skeletal muscle. In a separate experiment, 20 mg/rat of 1,2-[14C]linalool as a 10% solution in propylene glycol was administered intraperitoneally in male rats (Parke et al., 1974). More than 25% of the radioactivity in this latter study appeared in bile within the first 6-11 hours. No free linalool was detected. The authors concluded that extensive enterohepatic circulation of conjugates was occurring. In the presence of rat liver homogenates in vitro, linalool was rapidly oxidized by cytochrome P450 and conjugated with glucuronic acid (FEMA, 1998). Gavage administration of 600 mg/kg bwt/day of linalool as a suspension in 1% methyl cellulose for 1, 3 or 6 doses gave a 50% increase in liver cytochrome P-450 and 20% in cytochrome b5 after 3 days, with return to normal by 6 days (Chadha and Madyastha, 1984). In summary, the metabolic fate and disposition of dihydromyrcenol is anticipated to be similar to that of the structurally-related linalool. In particular, rapid conjugation of the parent compound or oxidized metabolites will occur with elimination primarily in the urine. Oxidative metabolism may become more important with repeated dosing. The in vitro dermal absorption of the analogue material, dimyrcetol, was determined under in-use (non-occluded) and occluded conditions using epidermal skin membranes from female cosmetic surgery donors. At a maximum use concentration of 6% in 70/30 (v/v) ethanol/water, 2.50 +/- 0.20% of Dimyrcetol A and 0.662 +/- 0.040% of Dimyrcetol B, respectively, were absorbed in 24 hours. These values include material that had permeated to receptor fluid as well as that present in the epidermis as determined from tape stripping. Overall dimyrcetol dermal absorption under non-occluded, in-use conditions was low as well as total recoveries of material under these conditions (2.36 +/- 0.24%). Overall 24 -hour absorption was increased to 10.4 +/- 1.2% and 2.13 +/- 0.15% for Dimyrcetol A and B, respectively, under occluded conditions. Overall recovery under occluded conditions increased also compared with non-occluded conditions with a value of 22.5 +/- 2.1% obtained. Significant losses due to evaporation were recorded under both non-occluded and occluded conditions. These losses due to evaporation are not incosistent with a material with a low measured vapor pressure given that under the conditions employed in the current studies, only a sparingly small amount of material was applied as a thin film, and given a slow rate of percutaneous absorption, the majority of material was lost before skin absorption could occcur. It is anticipated that such losses will also occur under in use conditions. Also, the increased dermal absorption for dimyrcetol component A may have been due in part to hydrolytic conversion from the formate ester.
Please refer to Section 13 of this IUCLID file for read-across documentation and rationale for the selection of representative analogue chemicals.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Route: .live2